口腔潜在恶性疾患的多模态风险评估:整合患者与标本数据
本文综述了患者相关因素(烟草酒精暴露、临床病变特征、全身健康因素、口腔健康指数)和标本相关数据(组织病理与分子 profiling、血液突变分析、唾液微生物与炎症标志物)对口腔潜在恶性疾患恶变风险的预测价值。结论指出恶变反映患者与标本风险通路的交叉,单一模态无法捕捉其复杂性,需协调扩展和标准化数据收集以开发多模态风险预测工具。
要点
- 组织病理学分级观察者间可靠性差且预后区分有限,需其他风险修饰因素。
- 患者相关因素包括烟草酒精暴露、临床病变特征、代谢综合征组分及口腔健康指数。
- 标本数据涵盖组织分子 profiling、血液突变及唾液微生物与炎症标志物。
核心结论
- 口腔潜在恶性疾患恶变风险异质,单一模态无法捕捉患者与标本风险通路的交叉复杂性。
- 实现口腔癌前病变精准预后需协调扩展和标准化各研究组的数据收集。
研究设计与样本
- 综述:检索 PubMed 中患者和标本来源因素与口腔癌及口腔潜在恶性疾患的文献,优先近5年系统综述和荟萃分析。
- 无系统综述时参考美国癌症协会、国家癌症研究所等指南或最新最佳文章。
主要发现
- 患者相关因素包括经验证的烟草和酒精暴露测量、临床病变特征、代谢综合征组分等全身健康因素、共病风险及口腔健康指数。
- 标本数据包括组织病理学和先进分子 profiling(基因组、表观基因组、转录组、空间方法)、血液胚系和体细胞突变分析、唾液微生物组和炎症生物标志物评估。
临床怎么用
- 本综述旨在指导前瞻性研究设计的协变量选择,提高可重复性,最终推动临床可用的多模态风险预测工具开发。
局限性
- 组织病理学异型增生分级作为参考标准观察者间可靠性差且预后区分有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral potentially malignant disorders exhibit heterogeneous malignant transformation risk that clinical approaches fail to adequately predict. Histopathologic dysplasia grading, the reference standard of risk assessment, is associated with poor interobserver reliability and limited prognostic discrimination. It is necessary to define other potential patient- and tissue-associated risk modifiers to improve patient-specific disease prediction. TYPES OF STUDIES REVIEWED: PubMed was queried for patient- and specimen-derived factors as they relate to oral cancer and oral potentially malignant disorders, with preference for systematic review and meta-analysis articles published within the past 5 years. When not available, guidelines from the American Cancer Society, National Cancer Institute, or other national organizations or the most recent best articles were referenced to support the data presented. RESULTS: Within patient-associated factors, validated measures of tobacco and alcohol exposure, clinical lesion characteristics, systemic health factors including metabolic syndrome components, comorbidity risk, and dental health indexes were found. Within specimen-derived data, tissue-based analyses encompassing histopathology and advanced molecular profiling (genomic, epigenomic, transcriptomic, spatial approaches), blood-based germline and somatic mutation analysis, and saliva-based microbiome characterization and inflammatory biomarker assessment were addressed. PRACTICAL IMPLICATIONS: Malignant transformation reflects intersecting patient and specimen risk pathways that affect each patient differently; no single modality captures this complexity. Realizing precision prognostication in oral precancer will require coordinated expansion and standardization of data collection across research groups. This review is intended to guide covariate selection for prospective study design, improve reproducibility, and ultimately enable the development of validated multimodal risk prediction tools for clinical deployment.
引用
- Troka ME, Villa A, Gates JC, et al. Multimodal risk assessment for oral potentially malignant disorders: Integrating patient-centered and specimen-derived data. J Am Dent Assoc. 2026. PMID: 42710994. doi:10.1016/j.adaj.2026.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。